John R. Stuelpnagel, Director at 10x Genomics, Inc. (TXG), sold 6,700 shares at $178.34 ($1.2M) on 2021-09-01, disclosed to the SEC on 2021-09-03.
Open-market sale of $1.2M TXG by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $175.36 | 300 | $53K | 4.4% |
| 2 | $175.36 | 300 | $53K | 4.4% |
| 3 | $176.36 | 1,000 | $176K | 14.8% |
| 4 | $177.62 | 2,300 | $409K | 34.3% |
| 5 | $178.34 | 1,104 | $197K | 16.5% |
| 6 | $178.34 | 1,104 |
| $197K |
| 16.5% |
| 7 | $179.15 | 296 | $53K | 4.5% |
| 8 | $179.15 | 296 | $53K | 4.5% |
| Total | $177.60 avg | 6,700 | $1.2M | 100% |
| Filing → |
| TXG | SELL | 2023-06-07 | $549K | — | Filing → |
| TXG | SELL | 2022-01-04 | $1.5M | — | Filing → |
| TXG | SELL | 2021-12-03 | $756K | — | Filing → |